Hospital CEO turnover rate peaks

Hospital CEO turnover is at the highest rate reported since the American College of Healthcare Executives (ACHE) began tracking the rate in 1981.

The turnover rate was 20 percent in 2013, according to ACHE, while the annual rate has fluctuated between 14 percent and 18 percent in the previous decade.

The turnover rate was 17 percent in 2012 and 16 percent in 2011 and 2010, respectively. The lowest reported rates were 13 percent in 1990 and 1983, according to ACHE.

The organization compiles the hospital CEO turnover rates based on changes in an organization's executive structure as reported to the American Hospital Association.

“The increase in the turnover rate may be indicative of a combination of factors, including an increased number of baby boomers seeking retirement, the emerging trend toward consolidation in our industry and the complexity and amount of change going on in healthcare today,” said Deborah J. Bowen, president and CEO of ACHE, in a written statement. “The increase in the rate reinforces the need for healthcare leaders to work with their boards to ensure appropriate succession plans are in place."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.